A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05540860 |
Recruitment Status :
Recruiting
First Posted : September 15, 2022
Last Update Posted : April 2, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Duchenne Muscular Dystrophy | Drug: EDG-5506 Dose 1 Drug: EDG-5506 Dose 2 Drug: EDG-5506 Dose 3 Drug: EDG-5506 Dose 4 Drug: EDG-5506 Dose 5 Drug: Placebo | Phase 2 |
The EDG-5506-210 protocol was amended to include an additional dose cohort and a cohort to include participants not currently treated with corticosteroids.
This is a 2-part, multi-center, Phase 2 study to evaluate the effect of EDG-5506 on safety, pharmacokinetics and biomarkers of muscle damage in approximately 54 children with DMD treated with oral, once-daily EDG-5506 for 24 months. This study will have up to a 4-week Screening period, a 12-week randomized, double-blind, placebo controlled treatment period (Part A), a 92-week open-label extension period (Part B), and a 2-week follow up period.
Approximately 54 participants aged 4 to 9 years inclusive will be randomized to EDG-5506 or placebo in a 2:1 ratio. Five dose cohorts (C1, C2, C3, C4 and C5) of approximately 9 participants each will be enrolled sequentially.
An additional cohort, Cohort 2NS, to include participants (aged 4 to 7 years inclusive) not currently treated with corticosteroids, will enroll approximately 9 participants after Cohort 2 safety review and in parallel with the additional cohorts.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 54 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B |
Actual Study Start Date : | October 24, 2022 |
Estimated Primary Completion Date : | February 2026 |
Estimated Study Completion Date : | February 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 Dose 1
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
Experimental: Cohort 2
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 Dose 2
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
Experimental: Cohort 3
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 Dose 3
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
Experimental: Cohort 4
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 Dose 4
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
Experimental: Cohort 5
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 Dose 5
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
Experimental: Cohort 2NS
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 Dose 2
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
- Number of adverse events during treatment with EDG-5506 or placebo [ Time Frame: 24 months ]All participants
- Severity of adverse events during treatment with EDG-5506 or placebo [ Time Frame: 24 months ]All participants
- Incidence of abnormal clinical chemistry test results [ Time Frame: 24 months ]All participants
- Incidence of abnormal hematology test results [ Time Frame: 24 months ]All participants
- Incidence of abnormal coagulation test results [ Time Frame: 24 months ]All participants
- Incidence of abnormal urinalysis test results [ Time Frame: 24 months ]All participants
- Pharmacokinetics as measured by steady state plasma concentration [ Time Frame: 24 months ]All participants
- Change from Baseline in serum creatinine kinase [ Time Frame: 12 weeks ]All participants
- Change from Baseline in fast skeletal muscle troponin I [ Time Frame: 12 weeks ]All participants
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 4 Years to 9 Years (Child) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Key Common Inclusion Criteria:
- A documented mutation on the DMD gene and phenotype consistent with Duchenne muscular dystrophy.
- Able to complete the stand from supine in ≤ 10 seconds and able to perform the 4-stair climb in < 10 seconds at the Screening visit.
- Body weight greater than or equal to 15 kg and less than 35 kg at the Screening visit.
For Cohorts 1, 2, 3, 4 and 5:
Aged 4-9 years on a stable dose of corticosteroids for a minimum of 6 months prior to the Baseline visit.
For Cohort 2 Non-Steroid (Cohort 2NS):
Aged 4-7 years not on corticosteroids within 6 months prior to the Baseline visit.
Key Common Exclusion Criteria:
- Medical history or clinically significant physical exam/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes venous access that would be too difficult to facilitate repeated blood testing.
- A forced vital capacity < 60% predicted at the Screening visit for those participants who are > 8 years old at Screening.
- A cardiac echocardiography showing left ventricular ejection < 45% at the Screening visit.
- Receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) of the Screening visit in the present study.
- Receipt of a stable dose of an approved exon-skipping therapy with a treatment duration of less than 1 year prior to the Screening visit.
For Cohort 2 Non-Steroid (Cohort 2NS):
Receipt of oral corticosteroids for the treatment of Duchenne muscular dystrophy in the previous 6 months. Participants will not be tapered off steroids for the purpose of this study and oral corticosteroids for the treatment of Duchenne muscular dystrophy may be initiated after the Week 16 visit.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05540860
Contact: Edgewise Therapeutics | 720-262-7002 | studies@edgewisetx.com |
United States, Arkansas | |
Arkansas Children's Hospital | Recruiting |
Little Rock, Arkansas, United States, 72202 | |
United States, California | |
UCLA Medical Center | Recruiting |
Los Angeles, California, United States, 90095 | |
UC Davis Medical Center | Recruiting |
Sacramento, California, United States, 95817 | |
United States, Colorado | |
Children's Hospital Colorado | Recruiting |
Aurora, Colorado, United States, 80045 | |
United States, Florida | |
University of Florida | Recruiting |
Gainesville, Florida, United States, 32610 | |
United States, Georgia | |
Rare Disease Research | Recruiting |
Atlanta, Georgia, United States, 30329 | |
United States, Iowa | |
University of Iowa | Recruiting |
Iowa City, Iowa, United States, 52242 | |
United States, Kansas | |
University of Kansas Medical Center | Recruiting |
Kansas City, Kansas, United States, 66160 | |
United States, Maryland | |
Kennedy Krieger Institute | Recruiting |
Baltimore, Maryland, United States, 21205 | |
United States, Massachusetts | |
University of Massachusetts Memorial Medical Center | Recruiting |
Worcester, Massachusetts, United States, 01605 | |
United States, Missouri | |
Washington University School of Medicine | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
United States, Ohio | |
Cincinnati Children's Hospital | Recruiting |
Cincinnati, Ohio, United States, 45229 | |
Nationwide Children's Hospital | Recruiting |
Columbus, Ohio, United States, 43205 | |
United States, Texas | |
Cook Children's Medical Center | Recruiting |
Fort Worth, Texas, United States, 76104 |
Responsible Party: | Edgewise Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT05540860 |
Other Study ID Numbers: |
EDG-5506-210 |
First Posted: | September 15, 2022 Key Record Dates |
Last Update Posted: | April 2, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Duchenne Muscular Dystrophy |
Muscular Dystrophies Muscular Dystrophy, Duchenne Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases |
Neuromuscular Diseases Nervous System Diseases Genetic Diseases, Inborn Genetic Diseases, X-Linked |